Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2013 February;79(2) > Minerva Anestesiologica 2013 February;79(2):200-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

EXPERT OPINIONS  


Minerva Anestesiologica 2013 February;79(2):200-8

language: English

Colistin in critically ill patients

Boisson M. 1, 2, Gregoire N. 1, Couet W. 1, 3, Mimoz O. 1, 2

1 Inserm U1070, Faculty of Medicine and Pharmacy, University of Poitiers, Poitiers, France;
2 Department of Anesthesiology and Intensive Care Unit, University Hospital of Poitiers, Poitiers, France;
3 Toxicology and Pharmacokinetic Unit, University Hospital of Poitiers, Poitiers, France


FULL TEXT  


Colistin is a re-emerging old antibiotic that is used as a salvage treatment against multidrug-resistant Gram-negative infections. Because it is administrated as an inactive prodrug, colistin methanesulfonate (CMS) that undergoes rapid hydrolyze to colistin, pharmacokinetic studies using biological assays are unreliable. With the recent development of new assays using high performance liquid chromatography (HPLC) accurate pharmacokinetic of CMS and formed colistin is now available in various populations. This article aims to update previous reports on pharmacodynamics, pharmacokinetics, safety and clinical use of colistin, with a special focus on data useful to treat critically ill patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail

matthieu.boisson@univ-poitiers.fr